Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan

AbstractTo evaluate the incidence of secondary primary malignancy (SPM) in patients with ovarian cancer using a nationwide retrospective population-based dataset.Patients newly diagnosed with ovarian cancer between 1997 and 2010 were identified using Taiwan's National Health Insurance database. Patients with antecedent malignancies were excluded. Standardized incidence ratios (SIRs) for SPM were calculated and compared with the cancer incidence in the general population. Risk factors for cancer development were analyzed using Cox proportional hazard models. Effects of surgery, chemotherapy, and radiotherapy after ovarian cancer diagnosis were regarded as time-dependent variables to prevent immortal time bias.During the 14-year study period (follow-up of 56,214 person-years), 707 cancers developed in 12,127 patients with ovarian cancer. The SIR for all cancers was 2.78 (95% confidence interval 2.58–3.00). SIRs for follow-up periods of >5, 1–5, and <1 year were 1.87, 2.04, and 6.40, respectively. After the exclusion of SPM occurring within 1 year of ovarian cancer diagnosis, SIRs were significantly higher for cancers of the colon, rectum, and anus (2.14); lung and mediastinum (1.58); breast (1.68); cervix (1.65); uterus (7.96); bladder (3.17), and thyroid (2.23); as well as for leukemia (3.98) and others (3.83). Multivariate analysis showed that age ≥ 50 years was a significant SPM risk factor (hazard ratio [HR] 1.60). Different treatments for ovarian cancer, including radiotherapy (HR 2.07) and chemotherapy (HR 1.27), had different impacts on SPM risk.Patients with ovarian cancer are at increased risk of SPM development. Age ≥ 50 years, radiotherapy, and chemotherapy are independent risk factors. Close surveillance of patients at high risk should be considered for the early detection of SPM.

[1]  W. Chung,et al.  BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high‐risk pancreatic cancer screening and pancreatic cancer cohorts , 2014, Cancer.

[2]  T. Rebbeck,et al.  Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[3]  Christopher I Amos,et al.  Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Lubiński,et al.  Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families , 2013, Molecular Biology Reports.

[5]  H. Chung,et al.  Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer , 2013, BMC Cancer.

[6]  R. Eeles,et al.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. , 2013, Journal of the National Cancer Institute.

[7]  T. Opala,et al.  Life style and risk of development of breast and ovarian cancer. , 2012, Annals of agricultural and environmental medicine : AAEM.

[8]  H. Song,et al.  Metachronous Double Primary Cancer after Diagnosis of Gastric Cancer , 2012, Cancer research and treatment : official journal of Korean Cancer Association.

[9]  Henrik Toft Sørensen,et al.  Chronic obstructive pulmonary disease and cancer risk: a Danish nationwide cohort study. , 2012, Respiratory medicine.

[10]  I. Gram,et al.  Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition , 2011, British Journal of Cancer.

[11]  Laetitia Huiart,et al.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. , 2011, JAMA.

[12]  V. Emirdar,et al.  Second primary cancers following borderline ovarian tumors , 2011, Archives of Gynecology and Obstetrics.

[13]  E. Björnsson,et al.  Increased risk for malignant neoplasms among patients with cirrhosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  G. Feldman,et al.  Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 , 2010, Genetics in Medicine.

[15]  C. Vecchia,et al.  Second neoplasms after invasive and borderline ovarian cancer , 2009, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[16]  G. Vlastos,et al.  Increased risk of second cancer among patients with ovarian borderline tumors. , 2008, Gynecologic oncology.

[17]  W. Brewster,et al.  Epithelial Ovarian Cancer and Low Malignant Potential (LMP) Tumors Associated With a Lower Incidence of Second Primary Breast Cancer , 2007, American journal of clinical oncology.

[18]  Michael I. Jordan,et al.  Statistical modeling of biomedical corpora: mining the Caenorhabditis Genetic Center Bibliography for genes related to life span , 2006, BMC Bioinformatics.

[19]  J. Satagopan,et al.  Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. , 2004, Journal of the National Cancer Institute.

[20]  Ronit Almog,et al.  BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. , 2004, Journal of the National Cancer Institute.

[21]  Tsung-Mei Cheng.  Taiwan's new national health insurance program: genesis and experience so far. , 2003, Health affairs.

[22]  S. Kehoe,et al.  Prior, synchronous and secondary malignancies in women with ovarian cancer , 2001, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[23]  F. Levi,et al.  Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms , 1999, British Journal of Cancer.

[24]  K. Shiromizu,et al.  Familial risk factors for a second primary malignancy in endometrial or ovarian carcinoma. , 1995, Journal of obstetrics and gynaecology.

[25]  A. Cavaliere,et al.  5-Fluorouracil Carcinogenesis in BALB/c MICE , 1990, Tumori.

[26]  N. Day,et al.  Second malignancies following testicular cancer, ovarian cancer and hodgkin's disease: An international collaborative study among cancer registries , 1987, International journal of cancer.

[27]  N. Day,et al.  Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. , 1987, British Journal of Cancer.

[28]  Y. Otani,et al.  Multiple primary cancers in the stomach and another organ: frequency and the effects on prognosis. , 1985, Japanese journal of clinical oncology.

[29]  A. Kagan,et al.  Secondary neoplasms in treated ovarian cancer. , 1982, Gynecologic oncology.

[30]  R. Hoover,et al.  Second primary neoplasms following ovarian cancer. , 1978, Journal of the National Cancer Institute.

[31]  F. Sung,et al.  Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients , 2013, International journal of cancer.

[32]  P. Hall,et al.  Overestimated risk of second primary malignancies in ovarian cancer patients. , 2000, European Journal of Cancer.

[33]  J. Pater,et al.  Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  L. Drucker,et al.  Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. , 2000, Anticancer research.

[35]  J. Bernheim,et al.  A second primary malignancy in a cohort of patients with epithelial ovarian cancer--characteristics of diagnosis. , 1998, European journal of gynaecological oncology.

[36]  N. Day,et al.  A case-control study of leukaemia as a second primary malignancy following ovarian and breast neoplasms. , 1986, IARC scientific publications.

[37]  IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: general remarks on the substances considered. , 1978, IARC monographs on the evaluation of the carcinogenic risk of chemicals to man.

[38]  B. J. Masterson,et al.  Multiple threat: second primary malignancies in patients with ovarian carcinoma treated with radiation and chemotherapy. , 1977, The Journal of the Kansas Medical Society.